Cellebrite DI (NASDAQ:CLBT) Price Target Cut to $15.00 by Analysts at Lake Street Capital

Cellebrite DI (NASDAQ:CLBT) had its price objective lowered by Lake Street Capital from $21.00 to $15.00 in a report released on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

CLBT has been the subject of several other reports. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC cut their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday. JPMorgan Chase & Co. cut their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, DA Davidson dropped their price objective on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average price target of $16.70.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $11.14 on Friday. The company has a market capitalization of $2.78 billion, a PE ratio of 50.64, a PEG ratio of 1.34 and a beta of 1.18. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.98. The business has a fifty day moving average price of $14.47 and a 200-day moving average price of $14.03.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, August 13th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.05. The firm had revenue of $131.14 million during the quarter, compared to analysts’ expectations of $131.50 million. Cellebrite DI had a return on equity of 16.04% and a net margin of 11.43%. On average, sell-side analysts anticipate that Cellebrite DI will post 0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO David Barter sold 41,734 shares of the business’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas E. Hogan sold 139,713 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total value of $2,150,183.07. Following the completion of the sale, the chief executive officer owned 790,548 shares of the company’s stock, valued at $12,166,533.72. This trade represents a 15.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 297,934 shares of company stock worth $4,631,972 in the last 90 days. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Elevation Wealth Partners LLC acquired a new stake in shares of Cellebrite DI in the second quarter valued at $44,000. Moody National Bank Trust Division increased its stake in Cellebrite DI by 7.6% in the second quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock valued at $886,000 after purchasing an additional 4,284 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Cellebrite DI by 91.1% during the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock worth $105,000 after purchasing an additional 3,626 shares in the last quarter. Alpine Woods Capital Investors LLC acquired a new stake in Cellebrite DI during the first quarter worth approximately $223,000. Finally, Evolutionary Tree Capital Management LLC lifted its position in shares of Cellebrite DI by 22.6% during the 1st quarter. Evolutionary Tree Capital Management LLC now owns 183,473 shares of the company’s stock worth $2,528,000 after buying an additional 33,829 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Key Headlines Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.